Plenty including clinical safety, regulatory, any delays or...

Plenty including clinical safety, regulatory, any delays or negative results from the TBI study could undermine investor confidence in the broader potential of NYR-BI03 and delay further developments, Phase Ia trial may not align with these results in humans

1. • the first human trial (Phase Ia) will test NYR-BI03 in healthy volunteers. There's always the potential for unforeseen safety issues when transitioning from animals to humans.
   • Efficacy failure: While preclinical results are promising, the drug may not show the same positive results in human trials, especially as human biology can differ from animal models.
   • Delays in trial recruitment: Recruitment for clinical trials can sometimes take longer than expected, leading to delays in dosing or trial completion.

hole heap of things. it's early days